Abstract
Pretargeted delivery of radionuclides is based upon bispecific immunoconjugates that bind a target tumor antigen and a small molecule carrying the active payload. This strategy is supposed to combine the advantage of antibodies to track tumor cells in vivo and of small radiolabeled molecules that clear rapidly from normal organs and minimize toxicity. Many pretargeting approaches have been proposed, but only those using the biotin / avidin recognition system and those using bispecific anti-tumor x anti-hapten antibodies have been tested in the clinic for both immunoscintigraphy and radioimmunotherapy. Their respective advantages and drawbacks, as well as hurdles in the way of an effective therapy against solid tumors, are discussed. In the light of the encouraging results obtained so far in the clinic, pretargeting remains a most promising challenge for chemistry and biotechnology.
Keywords: pretargeting, immunoscintigraphy, radioimmunotherapy, antibodies, cancer
Current Medicinal Chemistry
Title: Recent Advances in Pretargeted Radioimmunotherapy
Volume: 12 Issue: 3
Author(s): A. Gruaz-Guyon, O. Raguin and J. Barbet
Affiliation:
Keywords: pretargeting, immunoscintigraphy, radioimmunotherapy, antibodies, cancer
Abstract: Pretargeted delivery of radionuclides is based upon bispecific immunoconjugates that bind a target tumor antigen and a small molecule carrying the active payload. This strategy is supposed to combine the advantage of antibodies to track tumor cells in vivo and of small radiolabeled molecules that clear rapidly from normal organs and minimize toxicity. Many pretargeting approaches have been proposed, but only those using the biotin / avidin recognition system and those using bispecific anti-tumor x anti-hapten antibodies have been tested in the clinic for both immunoscintigraphy and radioimmunotherapy. Their respective advantages and drawbacks, as well as hurdles in the way of an effective therapy against solid tumors, are discussed. In the light of the encouraging results obtained so far in the clinic, pretargeting remains a most promising challenge for chemistry and biotechnology.
Export Options
About this article
Cite this article as:
Gruaz-Guyon A., Raguin O. and Barbet J., Recent Advances in Pretargeted Radioimmunotherapy, Current Medicinal Chemistry 2005; 12 (3) . https://dx.doi.org/10.2174/0929867053363225
DOI https://dx.doi.org/10.2174/0929867053363225 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets The Role of the Complex USP1/WDR48 in Differentiation and Proliferation Processes in Cancer Stem Cells
Current Stem Cell Research & Therapy Subject Index To Volune 2
Current Cancer Therapy Reviews Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mini-Reviews in Medicinal Chemistry The Problem of Amino Acid Complementarity and Antisense Peptides
Current Protein & Peptide Science Nanocarriers for Effective Brain Drug Delivery
Current Topics in Medicinal Chemistry Network Pharmacology Analysis of Molecular Mechanism of Curcuma longa L. Extracts Regulating Glioma Immune Inflammatory Factors: Implications for Precise Cancer Treatment
Current Topics in Medicinal Chemistry The Interactions of the 5-HT3 Receptor with Quipazine-Like Arylpiperazine Ligands. The Journey Track at the End of the First Decade of the Third Millennium
Current Topics in Medicinal Chemistry Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design The Role of microRNAs in Gliomas – Therapeutic Implications
Current Molecular Pharmacology Recent Progress in Gene Therapy for Parkinson’s Disease
Current Molecular Medicine Recent Developments of Phototherapy Based on Graphene Family Nanomaterials
Current Medicinal Chemistry Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry